Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese hepatocellular carcinoma (HCC; the most prevalent type of primary liver cancer) market will quadruple between 2006 and 2011. According to the new Emerging Markets report entitled Liver Cancer in China, this growth will be fueled by increasing access to medical care, increased sales of existing therapies, and the introduction of novel targeted agents.

The report also finds that the small-molecule tyrosine kinase inhibitors will dominate the Chinese HCC market through 2011 because of the superior efficacy and safety profiles of these agents. Chinese manufactured targeted biologics are another group of agents that will register significant growth over the 2006-2011 period and compete with Western manufactured targeted agents.

Cost is much more of a constraint on HCC treatment in China than in Western nations. Forty-four percent of physicians surveyed believe that high drug prices are a key challenge that limits effective management of HCC. The high cost of some therapies, particularly Western branded medications and molecular targeted agents, directly affects patient compliance and persistence and, in turn, patient prognosis.

"More than 50% of liver cancer cases worldwide occur in China, because of the pandemic status of hepatitis B and hepatitis C in this country," said Victor Li, Ph.D., analyst at Decision Resources. "Therapies with superior efficacy and fewer side effects, such as Bayer's Nexavar, will enjoy great commercial success in China's liver cancer market."

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

  --  More accurately assess their commercial opportunity for Western brands       in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou       - and in the high-growth second-tier markets of Tianjin, Wuhan,       Nanjing, Hangzhou, and Jinan.   --  Understand the physician treatment patterns and drivers of choice in       key first- and second-tier cities based on primary research.   --  Gain a clear perspective of the Chinese 5-year market forecast at the       drug level, broken out by urban and rural areas, and by sales from       multinational and Chinese-based companies.    About Decision Resources 

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or emarshall@dresources.com

Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting

View Now